Medipath
Medipath is a French private network of 50+ pathology centers processing 1.5 million cancer diagnostic cases annually for patients, prescribing physicians, and government screening programs, augmented by digital pathology and third-party AI tools.
- Company typePrivate
- Founded1999
- HeadquartersFréjus, France
- Headcount251–500
- GTM typeB2B
- OfferingServices
What Medipath does
Medipath is a French private network of independent pathology practices specializing in anatomical and cytological pathology, with a core focus on cancer screening and diagnosis. Founded in 1999 and headquartered in Fréjus, the company operates 50+ pathology centers across France staffed by 500+ collaborators, including 100+ molecular pathologists and 100+ physicians, processing approximately 1.5 million patient dossiers per year. Medipath participates in French government-organized cancer screening programs for breast, cervical, and colorectal cancer, and positions itself as the first clinical step in cancer patient care pathways.
The company's core technology stack is built on digital pathology: Medipath was the first worldwide user of SG300 high-performance slide scanners, enabling digitization of microscope slides for pathologist review, remote expertise, and AI-assisted diagnosis. AI capability is assembled through partnerships with multiple vendors — IBEX (prostate and breast), OWKIN (colorectal), PRIMAA (skin), VITADX (bladder), and HOLOGIC (cervical) — integrated into the diagnostic workflow rather than developed in-house. Service offerings include the One Day Diag program (24-hour diagnosis for breast and thyroid anomalies at partner expert centers), the M3P patient-pathologist consultation program (€60 per consultation, fully reimbursed for ALD patients), and the My Medipath Patient portal (launched March 2025) for online access to results, payments, and insurance tele-transmission.
Medipath's revenue model is primarily professional services: pathology diagnostic analysis billed to Assurance Maladie (Sécurité Sociale) under regulated tariffs, with supplementary reimbursement from private insurers. Patient-facing services (M3P, portal-driven administrative services) add a modest direct-revenue and engagement layer. The go-to-market combines a B2B sales-led motion (healthcare professional referrals, courier-based sample logistics, hospital partnerships) with limited direct-to-consumer elements (M3P consultations, Doctolib booking). The group is owned and operated by liberal pathologists with no disclosed external investors, no parent company, and no funding rounds on record.
Medipath firmographics
Firmographics- Name
- Medipath
- Legal name
- Medipath, société d'exercice libéral par action simplifiée
- Website
- https://medipath.fr
- Company type
- Private
- Founded year
- 1999
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Medipath is a French private network of 50+ pathology centers processing 1.5 million cancer diagnostic cases annually for patients, prescribing physicians, and government screening programs, augmented by digital pathology and third-party AI tools.
- Ownership category
- akta.pro rank
Medipath industry classification
Industry- Product category
- Pathology Diagnostics Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071), Services-Health Services (8000)
- akta.pro primary industry
- Anatomic Pathology (Histopathology & Cytopathology) (HLAFAMAA)
- akta.pro secondary industries
- Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays) (HLAAALAI), Pathology Reporting, Synoptic Templates & Cancer Registry Interfaces (HLACAMAJ), Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD), Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)
Keywords
Where Medipath is headquartered
LocationHeadquarters
- HQ city
- Fréjus
- HQ country
- France
- HQ region
- Europe
Offices9 records
Markets served
Medipath business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel
Revenue model
- Pathology Analysis Services: Medipath provides anatomical and cytological pathology diagnostic services. Revenue is generated through medical analysis billing to national health insurance (Sécurité Sociale) and supplementary health insurance providers. The company handles sample collection, transport, analysis, medical validation, and report transmission.
- M3P Patient Consultations: Direct patient consultations with pathologists for diagnosis explanation. The consultation fee is €60, with 100% coverage by national health insurance for patients with ALD (Affection Longue Durée). Third-party payment (tiers payant) is applicable.
- Patient Portal Services: Online services including access to medical history, invoice viewing and payment, electronic transmission of care sheets to insurance, and retrieval of payment attestations through the My Medipath Patient platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Per occurrence | M3P Consultation - Standard |
Go-to-market motion2 records
Distribution channels6 records
Marketing channels6 records
Medipath product offering
Product offeringCore offering
Medipath operates a nationwide network of 50+ pathology centers in France providing anatomical and cytological pathology diagnostic services for cancer detection and screening. The company processes 1.5 million pathology dossiers annually, leveraging digital pathology with SG300 slide scanners and AI-augmented diagnostic tools across multiple cancer types. Its portfolio includes core pathology analysis, the One Day Diag rapid 24-hour diagnosis program for breast and thyroid cancer, and the M3P direct patient-pathologist consultation service.
Product overview
Medipath is a network of independent pathology practices offering anatomical and cytological pathology diagnostic services for cancer detection and diagnosis across France. The portfolio includes core pathology services (handling 1.5 million cases annually), One Day Diag rapid diagnostic programs, M3P patient-pathologist consultation services, and digital pathology platforms. AI-powered diagnostic tools (IBEX, OWKIN, PRIMAA, VITADX, HOLOGIC) assist pathologists across prostate, breast, colorectal, skin, bladder, and cervical cancers. Patient-facing services include the My Medipath Patient Portal for accessing results and payments, while healthcare professionals use dedicated portals for sample management and result access.
Differentiator
Problem solved
Functional benefit
Brands
- My Medipath Patient: Patient portal platform providing access to medical history, online payment of invoices, and insurance tele-transmission.
- One Day Diag
- M3P (Médecin-Malin-Patient)
Products and services
- One Day Diag Same-day diagnostic service providing rapid diagnosis within 24 hours for breast and thyroid cancer abnormalities, offered to patients with clinical symptoms or radiological anomalies through expert partner healthcare centers.
- M3P (Moments de Méthode Pathologique) Direct consultation program enabling patients to meet with pathologists who present and explain digitized examination images, answer questions about pathology reports, and provide clarity on diagnoses. Priced at €60 per consultation with full coverage by French national health insurance for ALD patients.
- Digital Pathology Platform Digital pathology platform using SG300 high-performance slide scanners to digitize microscope slides, enabling augmented pathology review, remote expertise sharing, case sharing for training or diagnostic purposes, and integration with AI diagnostic tools.
- AI Diagnostic Tools Suite (IBEX, OWKIN, PRIMAA, VITADX, HOLOGIC) Integrated suite of AI-powered computer vision diagnostic tools assisting pathologists in cancer detection across multiple cancer types: prostate, breast, colorectal, skin, bladder, and cervical cancers.
- My Medipath Patient Portal Secure online platform for patients to access medical records, view and pay invoices, download payment attestations, electronically transmit care sheets to health insurance, and receive SMS/email notifications when results become available.
- Healthcare Professional Portal Secure online portal for healthcare professionals to access result servers, manage sample submissions via dedicated forms with configurable pickup frequencies, and coordinate patient care across the Medipath network.
- Organized Cancer Screening Services Diagnostic pathology services delivered as part of the French government-organized national cancer screening programs for breast cancer (women aged 50-74), cervical cancer (women aged 25-65), and colorectal cancer (men and women aged 50-74).
- Molecular Pathology Services Molecular pathology diagnostics and analysis services for cancer, supported by a network of 100+ molecular pathologists across the centers, providing expertise on molecular markers for diagnosis and treatment selection.
Quantifiable outcome
- 1.5 million dossiers (cases) processed per year across the network
- +2 more outcomes
Companies that use Medipath
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Medipath technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature8 records
Medipath partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered core, major and minor.
- IBEXcoreAI diagnostic partnership for prostate and breast cancer detection. IBEX provides artificial intelligence technology integrated into Medipath's diagnostic workflow to enhance accuracy and efficiency of cancer detection.
- OWKINcoreAI diagnostic partnership for colorectal cancer. OWKIN provides machine learning and AI solutions for colorectal cancer analysis, integrated into Medipath's pathology services.
- PRIMAAcoreAI diagnostic partnership for skin cancer detection. PRIMAA provides artificial intelligence technology for analyzing skin lesions and detecting skin cancer.
- VITADXcoreAI diagnostic partnership for bladder cancer. VITADX provides specialized artificial intelligence solutions for bladder cancer diagnostic analysis.
- HOLOGICcoreAI diagnostic partnership for cervical cancer screening. HOLOGIC provides AI-powered systems for cervical cancer detection and screening integrated into Medipath's services.
- ICM Mougins (Institut Cancerologie Mougins)majorPartner healthcare establishment in Provence-Alpes-Côte d'Azur region for the One Day Diag breast cancer rapid diagnosis program. ICM Mougins hosts the same-day diagnostic pathway in collaboration with Medipath.
- BioServeur – DedaluscoreTechnology subcontractor providing the results server infrastructure. Dedalus (through BioServeur) provides and maintains the medical results server used by Medipath for secure results delivery.
- Agence LafabminorWebsite development agency responsible for Medipath's internet site (medipath.fr).
- French Government and Assurance MaladiecoreGovernment-backed organized cancer screening programs for breast, cervical, and colorectal cancer. The French government and national health insurance (Assurance Maladie) deploy screening programs, with Medipath participating as a diagnostic provider.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
Medipath competitors and assessment
Company assessmentEmerging players
- Owkin: AI-for-pathology startup partnered with Medipath on colorectal cancer diagnostics; comparable as an AI-oncology platform whose direct-to-hospital distribution could overlap with Medipath's workflow.
- HalioDx (Veracyte): Oncology diagnostics company focused on tumor profiling and immune-based biomarker testing; comparable in the specialized anatomic pathology and oncology diagnostics niche.
- Eurofins Genoma (Eurofins Clinical Diagnostics France): Specialized genetics, molecular pathology, and clinical diagnostics provider; comparable in the molecular and specialty oncology diagnostics overlap with Medipath's molecular pathology services.
Broad incumbents
- Roche Diagnostics: Global IVD and digital pathology platform vendor (uPath) used by many pathology labs; comparable as an upstream technology incumbent whose digital pathology platform overlaps with Medipath's SG300-driven workflow.
Direct peers
- Biogroup: Major French medical laboratory network with broad geographic coverage; comparable as a multi-site private pathology/biology operator serving both patients and healthcare professionals.
- Cerba Healthcare: French-headquartered clinical and specialty pathology laboratory network serving hospitals and clinicians across Europe; directly comparable as a multi-site independent pathology group operating at national scale with similar customer mix.
- Inovie: One of the largest French private medical biology and pathology networks, operating hundreds of labs across France; directly comparable in scale, business model, and customer base.
- Centre de Pathologie de la Côte d'Azur / independent pathology groups: Regional independent pathology groups across France (e.g., centres concurrents en PACA); comparable as smaller, regional anatomic pathology practices competing for the same referrer and patient base.
- Unilabs: European clinical laboratory and diagnostics group with significant operations in France; comparable in offering clinical diagnostics and pathology services to patients and physicians at scale.
- Synlab: Pan-European medical diagnostics services provider with extensive pathology and laboratory operations; comparable as a large-scale clinical lab chain serving similar hospital and patient segments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Medipath social profiles
Digital presenceMedipath compliance and trust
Trust signalCompliance2 records
Medipath financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medipath leadership team
Management profileNumber of profiles
Profiles1 record
Medipath funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medipath M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medipath
What does Medipath do?
Medipath operates a nationwide network of 50+ pathology centers in France providing anatomical and cytological pathology diagnostic services for cancer detection and screening. The company processes 1.5 million pathology dossiers annually, leveraging digital pathology with SG300 slide scanners and AI-augmented diagnostic tools across multiple cancer types. Its portfolio includes core pathology analysis, the One Day Diag rapid 24-hour diagnosis program for breast and thyroid cancer, and the M3P direct patient-pathologist consultation service.
Is Medipath a public or private company?
Medipath is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Medipath founded?
Medipath was founded in 1999. It employs 251 to 500 people.
Where is Medipath based?
Medipath is headquartered in Fréjus, France, in the Europe region.
How does Medipath make money?
Three revenue lines are on record. Pathology Analysis Services are the primary driver. The others are M3P Patient Consultations and patient Portal Services.
Who are Medipath's main competitors?
Emerging players on record are Owkin, HalioDx (Veracyte) and Eurofins Genoma (Eurofins Clinical Diagnostics France). Roche Diagnostics is listed as a broad incumbent. Direct peers are Biogroup, Cerba Healthcare, Inovie, Centre de Pathologie de la Côte d'Azur / independent pathology groups, Unilabs and Synlab.
Does Medipath have an API?
No public API is recorded for Medipath.
What industry is Medipath in?
Medipath's product category is Pathology Diagnostics Services. Its primary akta.pro industry code is HLAFAMAA, Anatomic Pathology (Histopathology & Cytopathology), with a secondary code of HLAAALAI, Cytology & Histopathology Diagnostics (IHC, ISH, tissue-based assays). Its NAICS code is 621511 and its SIC code is 8071.